Vaccine Trials

“A phase I/II clinical trial to evaluate the safety and immunogenicity of a multiclade HIV-1 DNA plasmid vaccine boosted by a multiclade HIV-1 recombinant adenovirus-5 vector vaccine in HIV uninfected adult volunteers in East Africa”

Purpose

The objectives of the study were to evaluate the safety and immunogenicity of a multiclade A, B and C HIV DNA prime (VRC-HIVDNA016-00-VP) boosted with a multiclade A, B and C recombinant Adenovirus type 5 vector (VRC-HIVADV014-00-VP). The vaccine was provided by the NIH Vaccine Research Center (VRC) consisting of a multiclade A, B and C HIV DNA prime (VRC-HIVDNA016-00-VP) boosted with a multiclade A, B and C recombinant Adenovirus type 5 vector (VRC-HIVADV014-00-VP).

Team: Leonard Maboko (Principal Investigator), Mirjam Schunk, Arne Kroidl (Clinical Research Coordinator)

You can reach us at:

NIMR - Mbeya Medical Research Center
P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel +255 25 250 3364
Fax +255 25 250 3134

Working hours:
Mon - Fri
08:00 - 17:00 EAT (GMT + 3)

Or send us an email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Twitter Feed

NIMRMbeya RT @NIMR_Tanzania: NIMR is soliciting inputs from investigators and stakeholders to inform updating of the Data Transfer Agreement. Please…
12hreplyretweetfavorite
NIMRMbeya RT @NIMR_Tanzania: NIMR is soliciting inputs from investigators and stakeholders to inform updating of the Material Transfer Agreement (MTA…
12hreplyretweetfavorite
NIMRMbeya RT @EACCR2: World AIDS Day is here. Lets end HIV stigma and discrimination. Its our collective responsibility. #WAD2022 #WorldAidsDay2022 h…
15hreplyretweetfavorite
NIMRMbeya RT @NIMR_Tanzania: NIMR received a delegation from Zanzibar led by the Minister for Health Zanzibar Hon. Nassor Mazrui. He was accompanied…
NIMRMbeya RT @NIMR_Tanzania: An MoU between NIMR & ZAHRI was signed before the Minister for Health Zanzibar Hon. Nassor Mazrui. The MoU focuses on jo…
© 2017 NIMR - Mbeya Medical Research Center